Biden, Biden Administration, BioNtech, Comirnaty, Conflict of Interest, corruption, COVID-19, Covid-19 vaccines, divestment, Eric Lander, Ethics, ethics compliance, FDA approval Comirnaty, FDA approval impact on BioNTech stock, Pfizer, Pfizer-BioNTech, Pump and Dump, Stock market
Eric Lander, who is the Director of Biden’s Office of Science and Technology Policy, reported holding between half a million ($500,000) and a million dollars ($1,000,000) of BioNTech stock.
Biden’s FDA licensed German BioNTech’s Covid-19 vaccine (Comirnaty) on August 23, 2021.
On the morning of August 24, 2021, it was reported that shares of BioNTech had increased in value by 9.6% subsequent to the FDA’s announcement.
On August 25, 2021, Eric Lander filed the papers saying that he had divested his stock: “I have completed all of the divestitures indicated in the ethics agreement.” He had until September 2, 2021 to do so.
This looks akin to pump and dump stock scams.
Recall that Pfizer Covid-19 vaccine was not approved-licensed by the FDA, apart from Emergency Use Authorization. Rather, Germany’s BioNTech mRNA vaccine (Comirnaty), which is “legally distinct with certain differences” from the Pfizer vaccine, was approved, but with conditions. https://miningawareness.wordpress.com/2021/08/25/fda-only-renewed-emergency-use-authorization-for-pfizer-approval-was-for-biontechs-comirnaty-with-years-of-additional-safety-studies-required-thru-2027/
As the US NIH explained on September 13, 2021, the BioNTech vaccine, Comirnaty, was licensed on 8/23/2021 for use in individuals 16 and older, but none will be produced for the US market for months, while they get rid of the EUA stock: “At that time, the FDA published a BLA package insert that included the approved new COVID-19 vaccine tradename COMIRNATY and listed 2 new NDCs (0069-1000-03, 0069-1000-02) and images of labels with the new tradename. At present, Pfizer does not plan to produce any product with these new NDCs and labels over the next few months while EUA authorized product is still available and being made available for U.S. distribution. As such, the CDC, AMA, and drug compendia may not publish these new codes until Pfizer has determined when the product will be produced with the BLA labels”. https://dailymed.nlm.nih.gov/dailymed/dailymed-announcements-details.cfm?date=2021-09-13 http://web.archive.org/web/20210928041940/https://dailymed.nlm.nih.gov/dailymed/dailymed-announcements-details.cfm?date=2021-09-13
They have so much old EUA Pfizer-BioNTech stock, that they extended the expiration date by three months in both the US and Canada. Thus, they could be distributing the unlicensed EUA product as late as May of 2022, since expiration dates range from August to February 2022.
“Stock Market News for Aug 24, 2021
Zacks Equity Research Zacks
AUG 24, 2021 9:41AM: “On Aug 23, the U.S. Food and Drug Administration granted first approval to the COVID-19 vaccine developed by Pfizer Inc. PFE and BioNTech SE BNTX for people age 16 and above. The regulator also granted emergency-use authorization for those between 12 and 15 and for immunocompromised individuals who qualify for a third shot. Consequently, shares of Pfizer and BioNtech climbed 2.5% and 9.6%, respectively”. http://web.archive.org/web/20210825180222/https://www.nasdaq.com/articles/stock-market-news-for-aug-24-2021-2021-08-24
August 25 2021 divestiture:
Replace Montz with Lander to find the documents: https://extapps2.oge.gov/201/Presiden.nsf/201%20Request?OpenForm&Filer=Montz
Links are here:
Lander, Eric S Office of Science and Technology Policy, Director * https://extapps2.oge.gov/201/presiden.nsf/CEA15B79E467B470852586830032D92A/$FILE/Lander,%20Eric%20%20AMENDED%20finalEA.pdf